{"id":"W3032852436","doi":"10.1200/jco.2020.38.15_suppl.tps6101","title":"ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Carboplatin; Internal medicine; Bevacizumab; Oncology; Performance status; Urology; Maintenance therapy; Surgery; Chemotherapy; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002584992,0.002463226,0.002702597,0.0006504937,0.0004025552,0.001150885,0.00143455,0.002036056,0.008008599],"category_scores_gemma":[0.001550969,0.000944935,0.001452478,0.0005046439,0.001279922,0.001147415,0.0004151258,0.003600116,0.001267266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009861718,"about_ca_system_score_gemma":0.002100267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00092397,"about_ca_topic_score_gemma":0.002468637,"domain_scores_codex":[0.9994237,0.0002940283,0.00002423098,0.0000991769,0.00004596903,0.0001128788],"domain_scores_gemma":[0.9990627,0.0002060001,0.0002151964,0.00007314876,0.00004411041,0.0003989213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9432476,0.02926712,0.0008380776,0.0006589385,0.0004569138,0.00004519634,0.00006507243,0.0005470607,0.00528929,0.0002115822,0.001525971,0.01784735],"study_design_scores_gemma":[0.910341,0.08683817,0.001053744,0.00001990018,0.0001719576,0.00003570856,0.00001235198,0.0003177861,0.0004560207,0.0001072844,0.0006332613,0.00001272904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785123,0.002792899,0.0009292186,0.0007045314,0.0004706929,0.01100041,0.002502153,0.0003195126,0.002768264],"genre_scores_gemma":[0.9655907,0.002899032,0.004324537,0.001966528,0.0005137334,0.01460749,0.003376152,0.0000878787,0.006634015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008008599,"threshold_uncertainty_score":0.02679145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1912501473152218,"score_gpt":0.4841571363752475,"score_spread":0.2929069890600257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}